tbuckley/cabot-search huggingface dataset:
Abstract A14: Exploiting DNA damage repair defects to enhance PD-L1 expression in Ewing sarcoma
Authors: Lisa M. Maurer, Rose M. Venier, Claire Julian, Kelly M. Bailey
Journal: Cancer Research (2020)

Abstract Objective: The purpose of this work is to determine whether PD-L1 expression can be upregulated by PARP inhibitor treatment in Ewing tumor cells harboring DNA damage repair defects. Further, we aimed to determine whether enhanced PD-L1 expression renders Ewing cells more susceptible to T-cell mediated apoptosis following PD-1 inhibition. Experimental Procedures: Patient-derived tumor organoids and monolayers (named PSaRC-318) were established from a viably cryofrozen metastatic lung lesion from a patient with Ewing sarcoma and a paternally inherited germline BARD1 mutation. A673, CHLA9, and CHLA10 Ewing tumor cell lines were also employed. Sensitivity of PSaRC-318 to the PARP inhibitors olaparib and talazoparib was established by performing IncuCyte apoptosis assays. PD-L1 expression was examined using RT-PCR, Western blot, and flow cytometry. BARD1, BRCA, and RAD51D siRNA were also utilized to test the role of specific DNA damage repair proteins on this effect. T-cell/tumor cell cocultures and tumor-primed T-cells were established. T cell-induced tumor cell apoptosis was monitored in real-time using IncuCyte caspase and annexin assays. Results: PSaRC-318 organoids demonstrate exquisite sensitivity to PARP inhibitors, with an IC50 for talazoparib of 3.54nM. Treatment of PARP inhibitor-resistant Ewing cell lines, such as CHLA10, with BARD1 siRNA rendered cells sensitive to PARP inhibition. Ewing tumor cells were found to upregulate tumor cell surface expression of the checkpoint protein PD-L1 in response to treatment with PARP inhibitors. The impact of BARD1, BRCA1, and RAD51D on PD-L1 expression in Ewing tumor cells was also determined. Next, Ewing tumor cells were pretreated with PARP inhibitors and then cocultured with tumor-primed T-cells. T cell-mediated tumor cell apoptosis was monitored in real time using caspase IncuCyte assays. PD-1 blocking antibody added to T-cell/tumor cell cocultures resulted in an increase in early tumor cell death compared to IgG controls. Conclusion: Single-agent PARP inhibitors have not demonstrated significant clinical benefit in relapsed Ewing sarcoma to date, suggesting that combinatorial therapy with PARP inhibitors may be a more effective approach. Here, we have shown that Ewing tumor cells with germline mutations in DNA-damage repair proteins, such as BARD1, can upregulate PD-L1 expression following treatment with PARP inhibitors. Thus, PARP inhibitor/anti-PD-1 therapy may be a logical combination for the treatment of relapsed Ewing sarcoma. Ongoing preclinical studies are continuing to examine this combination. Citation Format: Lisa M. Maurer, Rose M. Venier, Claire Julian, Kelly M. Bailey. Exploiting DNA damage repair defects to enhance PD-L1 expression in Ewing sarcoma [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr A14.
Risk factors of community-onset extended-spectrum β-lactamase Escherichia coli and Klebsiella pneumoniae bacteraemia: an 11-year population-based case–control–control study in Denmark
Authors: Rasmus Richelsen, Jesper Smit, Pavithra Laxsen Anru, Henrik Carl Schønheyder, Henrik Nielsen
Journal: Clinical Microbiology and Infection (2020)
First report of hypermucoviscous Klebsiella variicola subsp. variicola causing primary endodontic infection
Authors: Rafael Nakamura-Silva, Luciana Martins Domingues Macedo, Louise Cerdeira, Mariana Oliveira-Silva, Yara Teresinha Correa Silva-Sousa, André Pitondo-Silva
Journal: Clinical Microbiology and Infection (2020)
Use of Bendamustine Combined with Rituximab in Chronic Lymphocytic Leukemia Patients: A Single Center Experience
Authors: Deniz Ozmen, Dilek Keskin, Nurgul Ozgur Yurttas, Sevil Sadri, Ayse Salihoglu, Ahmet Emre Eskazan, M. Cem Ar, Seniz Ongoren, Zafer Baslar, Teoman Soysal
Journal: Blood (2017)
Photo-functionalized TiO2 nanotubes decorated with multifunctional Ag nanoparticles for enhanced vascular biocompatibility
Authors: Jiang Chen, Sheng Dai, Luying Liu, Manfred F. Maitz, Yuzhen Liao, Jiawei Cui, Ansha Zhao, Ping Yang, Nan Huang, Yunbing Wang
Journal: Bioactive Materials (2020)

Titanium dioxide (TiO
AB1104 ANALYSIS OF ANTINUCLEAR ANTIBODY TITERS AND PATTERNS USING HEP 2 INDIRECT IMMUNOFLUORESCENCE IN VARIOUS LIVER DISEASES
Authors: Q. Wei, Y. Jiang, M. Yang, J. Xie, M. Xiao, J. Gu
Journal: Annals of the Rheumatic Diseases (2020)

Background: Abnormal liver function can be seen in not only hepatitis B virus infection (HBV), hepatitis C virus infection (HCV), hepatic carcinoma (HCC), but also in primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH), and systemic autoimmune rheumatic diseases (SARD). Antinuclear antibody (ANA) testing using indirect immunofluorescence assay (IIFA) is a common and economical method which contributes to detect SARD and autoimmune liver diseases [1]. Objectives: Our objective was to investigate ANA positivity, titers and their patterns in multiple liver diseases, including PBC, AIH, HBV, HCV, and HCC, compared to healthy controls (HC). Methods: 2537 patients with SARD, 137 PBC cases, 57 AIH cases, 3420 HBV cases, 769 HCV cases, 268 HCC cases, and 1073 HC were retrospectively assessed. The titers and patterns of ANA were detected with the IIFA method. Results: ANA positivity rate was considerably discernible between these diseases, which is 90.1% in SARD, 93.4% in PBC, 49.1% in AIH, 19.1% in HBV, 13.9% in HCV and 23.5% in HCC. Moreover, only 4.9% of HCC cases, 2.5% of HBV patients and 1.6% of HCV patients had an ANA titer ≥ 1:320. The mixed pattern which composed of at least two patterns majorly lied in PBC. AC-15 and AC-21 was frequently related to liver diseases; the former pattern was more frequently found in AIH (84.2%) and PBC (8.8%), and the latter pattern was easily seen in PBC (62.2%) and HCC (22.6%). The positive rate of ANA in HC was 12.2% and its major pattern was AC-2. Conclusion: There are differences in ANA positivity among patients with SARD and various liver diseases. Some mixed patterns may provide important evidence for the diagnosis of PBC. Clinicians should pay attention to ANA patterns and titer during the interpretation of this test. References: [1]Damoiseaux J, Andrade L, Carballo OG, Conrad K, Francescantonio P, Fritzler MJ, Garcia DLTI, Herold M, Klotz W, Cruvinel WM, Mimori T, von Muhlen C, Satoh M, Chan EK, (2019) Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. ANN RHEUM DIS 78: 879-889 Figure 1. The Proportion of Each ANA Pattern Exhibited in Different Diseases and HCANA: antinuclear antibodies; HC: healthy controls; PBC: primary biliary cirrhosis; AIH: autoimmune hepatitis; SARD: systemic autoimmune rheumatic diseases; HBV: hepatitis B virus infection: HCV: hepatitis C virus infection: HCC: hepatic carcinoma. Acknowledgments: None. Disclosure of Interests: None declared
Molecular Mismatch—the Renaissance of HLA in Kidney Transplantation
Authors: Chris Wiebe, Peter W. Nickerson
Journal: Journal of the American Society of Nephrology (2020)

The two most common causes of premature graft loss in renal transplantation, death with function and alloimmune-mediated injury, are inter-related; immunosuppressive medications used to prevent alloimmune injury also increase the risk of the most common causes of death with function ( i.e. , cardiac
Immune‐Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B–Infected Cells
Authors: Joannah R. Fergusson, Zoë Wallace, Mary M. Connolly, Amanda P. Woon, Richard J. Suckling, Dominic W. Hine, Claire Barber, Wilawan Bunjobpol, Beak‐San Choi, Sara Crespillo, Marcin Dembek, Nele Dieckmann, Jose Donoso, Luis F. Godinho, Tressan Grant, Dawn Howe, Michelle L. McCully, Carole Perot, Anshuk Sarkar, Florian U. Seifert, Praveen K. Singh, Kerstin A. Stegmann, Bethany Turner, Anil Verma, Andrew Walker, Sarah Leonard, Mala K. Maini, Katrin Wiederhold, Lucy Dorrell, Ruth Simmons, Andrew Knox
Journal: Hepatology (2020)

Therapies for chronic hepatitis B virus (HBV) infection are urgently needed because of viral integration, persistence of viral antigen expression, inadequate HBV-specific immune responses, and treatment regimens that require lifelong adherence to suppress the virus. Immune mobilizing monoclonal T Cell receptors against virus (ImmTAV) molecules represent a therapeutic strategy combining an affinity-enhanced T Cell receptor with an anti-CD3 T Cell-activating moiety. This bispecific fusion protein redirects T cells to specifically lyse infected cells expressing the target virus-derived peptides presented by human leukocyte antigen (HLA).
Impact of Molecular Testing on the Management of Indeterminate Thyroid Nodules Among Western and Asian Countries: a Systematic Review and Meta-analysis
Authors: Hanh Thi Tuyet Ngo, Truong Phan Xuan Nguyen, Trang Huyen Vu, Chan Kwon Jung, Lewis Hassell, Kennichi Kakudo, Huy Gia Vuong
Journal: Endocrine Pathology (2020)
Precision Nutrition—the Answer to “What to Eat to Stay Healthy”
Authors: Griffin P. Rodgers, Francis S. Collins
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Over-Expression of ERG Predicts Poor Outcome in Acute Myeloid Leukemia
Authors: Syed Khizer Hasan, Nikhil Patkar, Devanand Vishwakarma, Deepan Rajamanickam, Anant Gokarn, Arvind Sahu, Prashant Tembhare, Sadhana Kannan, Sumeet Gujral, Bhausaheb Bagal, Hasmukh Jain, Hari Menon, Manju Sengar, Pratibha Kadam Amare, Papagudi Ganesan Subramanian, Navin Khattry
Journal: Blood (2017)
Characteristics of CD4+ and CD8+ Memory T Cell Subsets from Peripheral and Bone Marrow in Patients with Acute Myeloid Leukemia
Authors: Ling Xu, Yao Danlin, Tan Jiaxiong, Yu Zhi, Chen Jie, Luo Gengxin, Lijian Yang, Zha Xianfeng, Shaohua Chen, Yangqiu Li
Journal: Blood (2017)
VT or Not VT?
Authors: Jeffrey Wagner, Jesse Fitzpatrick, Nora Goldschlager
Journal: Circulation (2020)

ECG CHALLENGEA 77-year-old man with a history of diabetes mellitus, hypertension, and paroxysmal atrial fibrillation, taking metoprolol tartrate 25 mg twice daily and flecainide 75 mg as needed for palpitations, presented to the emergency room with several hours of malaise and elevated heart rate to 127 bpm on home blood pressure cuff.Before arriving at the hospital, he self-administered flecainide 75 mg.Physical examination revealed heart rate 96 bpm, blood pressure 135/90 mm Hg, and oxygen saturation 98% on ambient air.Serum sodium was 138 mg/dL, serum potassium 3.90 mg/dL, serum magnesium 1.7 mg/dL, serum creatinine 0.88 mg/dL, and serum troponin-I <0.02 ng/mL (normal range, 0.00-0.04).The emergency room physician interpreted the ECG as showing atrial flutter with a 2:1 atrioventricular conduction ratio; the decision was made to administer an additional 200 mg of oral flecainide in an attempt to restore sinus rhythm.The patient's subsequent ECG 81 minutes after the initial ECG and 50 minutes following the flecainide 200 mg dose is shown in Figure 1.What is the rhythm, and how should it be treated?Please turn the page to read the diagnosis.
Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party
Authors: Jungmin Jo, Sung Hwa Bae, Jinny Park, Hong-ghi Lee, Chul Won Choi, Yong Park, Ho Sup Lee, Sung-Hyun Kim, Won-Sik Lee, Soo-Mee Bang, Jun-Ho Jang, Inho Kim, Je-Hwan Lee, June-Won Cheong, Seong Kyu Park, Jong-Ho Won, Min Kyoung Kim, Hyeok Shim, Yeung-Chul Mun, Jae-Sook Ahn, Deog-Yeon Jo, Dae Young Zang
Journal: Blood (2017)
A Critical Role for Donor-Derived IL-22 in Cutaneous Chronic Gvhd
Authors: Kate H Gartlan, Hemamalini Bommiasamy, Katelyn Paz, Andrew Wilkinson, Mary Owen, Dawn Reichenbach, Tatjana Banovic, Kimberly Wehner, Faith Buchanan, Antiopi Varelias, Rachel Kuns, Karshing Chang, Yuri Fedoriw, Thomas C. Shea, James M. Coghill, Michael Zaiken, Maximilian Plank, Paul Foster, Andrew Clouston, Bruce Blazar, Jonathan S Serody, Geoffrey R Hill
Journal: Blood (2017)
Lower gastrointestinal polypectomy competencies in the United Kingdom: a retrospective analysis of Directly Observed Polypectomy Skills (DOPyS)
Authors: Arun Rajendran, Siwan Thomas-Gibson, Paul Bassett, Paul Dunckley, Rajaratnam Rameshshanker, Nick Sevdalis, Adam Haycock
Journal: Endoscopy (2020)

Polypectomy is often the most hazardous part of colonoscopy. There is significant variability in polypectomy training and assessment internationally. DOPyS (Directly Observed Polypectomy Skills) is a validated assessment tool and is used to demonstrate polypectomy competency in the UK. This study aimed to describe the learning curve for polypectomy competency in UK trainees.Retrospective DOPyS data (January 2009 to September 2015) were obtained from the UK Joint Advisory Group (JAG) for intestinal endoscopy training system (JETS) national database. The number of lower gastrointestinal (LGI) procedures, overall cecal intubation rate (CIR), procedure intensity, and time in days to the first DOPyS assessment were recorded, and time to JAG certification was calculated.4965 DOPyS assessments from 336 trainees were analyzed. Within the study period, 124 and 53 trainees achieved provisional and full colonoscopy certification, respectively. Trainees started formative assessment of polypectomy after > 130 LGI procedures and with a CIR of > 70 %. Within 3 years from the first DOPyS assessment, 94 % of trainees achieved provisional certification, and 50 % full certification. Higher procedure intensity at baseline DOPyS assessment was associated with a higher likelihood of obtaining certification sooner.There is a significant variation in time to competency, and this potentially reflects the time necessary to acquire polypectomy skills. There is a need to start polypectomy training earlier, once sufficient skills, such as tip control, have been achieved to shorten the time to competency. Overall, the CIR could be used as a guide for such technical skills. Increasing exposure to training lists also potentially reduces the time to polypectomy competency.
Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes
Authors: Nidhi Gupta, Xinhua Wang, Xiaohui Wen, Paul Moran, Maciej Paluch, Philip E. Hass, Amy Heidersbach, Benjamin Haley, Daniel Kirchhofer, Randall J. Brezski, Andrew S. Peterson, Suzie J. Scales
Journal: Journal of the American Society of Nephrology (2020)

Significance Statement Two variants of circulating APOL1, G1 and G2, protect against subspecies of Trypanosoma brucei infection, but concurrently confer a greater risk of CKD. Little is known about the topology of APOL1 in HDL particles or on the podocyte cells affected in kidney disease. Antibodies generated along the length of APOL1 revealed differences of the exposed domains between serum and podocyte surface APOL1 topologies. These are the first direct insights into APOL1 conformations in physiological settings and have implications for development of APOL1-targeted drugs for APOL1 nephropathies. Background Circulating APOL1 lyses trypanosomes, protecting against human sleeping sickness. Two common African gene variants of APOL1 , G1 and G2, protect against infection by species of trypanosomes that resist wild-type APOL1. At the same time, the protection predisposes humans to CKD, an elegant example of balanced polymorphism. However, the exact mechanism of APOL1-mediated podocyte damage is not clear, including APOL1's subcellular localization, topology, and whether the damage is related to trypanolysis. Methods APOL1 topology in serum (HDL particles) and in kidney podocytes was mapped with flow cytometry, immunoprecipitation, and trypanolysis assays that tracked 170 APOL1 domain-specific monoclonal antibodies. APOL1 knockout podocytes confirmed antibody specificity. Results APOL1 localizes to the surface of podocytes, with most of the pore-forming domain (PFD) and C terminus of the Serum Resistance Associated-interacting domain (SRA-ID), but not the membrane-addressing domain (MAD), being exposed. In contrast, differential trypanolytic blocking activity reveals that the MAD is exposed in serum APOL1, with less of the PFD accessible. Low pH did not detectably alter the gross topology of APOL1, as determined by antibody accessibility, in serum or on podocytes. Conclusions Our antibodies highlighted different conformations of native APOL1 topology in serum (HDL particles) and at the podocyte surface. Our findings support the surface ion channel model for APOL1 risk variant–mediated podocyte injury, as well as providing domain accessibility information for designing APOL1-targeted therapeutics.
Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma
Authors: Rong Deng, Jun-Hao Huang, Yan Wang, Li-Huan Zhou, Zi-Feng Wang, Bing-Xin Hu, Yu-Hong Chen, Dong Yang, Jia Mai, Zhi-Ling Li, Hai-Liang Zhang, Yun Huang, Xiao-Dan Peng, Gong-Kan Feng, Xiao-Feng Zhu, Jun Tang
Journal: Molecular Cancer (2020)

Abstract Background Super-enhancers (SEs) play a crucial role in cancer, which is often associate with activated oncogenes. However, little is known about how SEs facilitate tumour suppression. Individuals with Down syndrome exhibit a remarkably reduced incidence of breast cancer (BC), moving the search for tumor suppressor genes on human chromosome 21 (HSA21). In this study, we aim to identify and explore potential mechanisms by which SEs are established for tumor suppressor RCAN1.4 on HSA21 in BC. Methods In silico analysis and immunohistochemical staining were used to assess the expression and clinical relevance of RCAN1.4 and RUNX3 in BC. Function experiments were performed to evaluate the effects of RCAN1.4 on the malignancy of breast carcinoma in vitro and in vivo. ChIP-seq data analysis, ChIP-qPCR, double-CRISPR genome editing, and luciferase reporter assay were utilized to confirm RUNX3 was involved in regulating RCAN1.4-associated SE in BC. The clinical value of co-expression of RCAN1.4 and RUNX3 was evaluated in BC patients. Results Here, we characterized RCAN1.4 as a potential tumour suppressor in BC. RCAN1.4 loss promoted tumour metastasis to bone and brain, and its overexpression inhibited tumour growth by blocking the calcineurin-NFATc1 pathway. Unexpectedly, we found RCAN1.4 expression was driven by a ~ 23 kb-long SE. RCAN1.4-SE distal was sensitive to BRD4 inhibition, and its deletion decreased RCAN1.4 expression by over 90% and induced the malignant phenotype of BC cells. We also discovered that the binding sites in the SE region of RCAN1.4 were enriched for consensus sequences of transcription factor RUNX3. Knockdown of RUNX3 repressed the luciferase activity and also decreased H3K27ac enrichment binding at the SE region of RCAN1.4. Furthermore, abnormal SE-driven RCAN1.4 expression mediated by RUNX3 loss could be physiologically significant and clinically relevant in BC patients. Notably, we established a prognostic model based on RCAN1.4 and RUNX3 co-expression that effectively predicted the overall survival in BC patients. Conclusions These findings reveal an important role of SEs in facilitating tumour suppression in BC. Considering that the combination of low RCAN1.4 and low RUNX3 expression has worse prognosis, RUNX3-RCAN1.4 axis maybe a novel prognostic biomarker and therapeutic target for BC patients.
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
Authors: Fathima Zumla Cader, Xihao Hu, Walter L. Goh, Kirsty Wienand, Jing Ouyang, Elisa Mandato, Robert Redd, Lee N. Lawton, Pei-Hsuan Chen, Jason L. Weirather, Ron C. J. Schackmann, Bo Li, Wenjiang Ma, Philippe Armand, Scott J. Rodig, Donna Neuberg, X. Shirley Liu, Margaret A. Shipp
Journal: Nature Medicine (2020)
Leptomeningeal metastases: how best to assess response
Authors: Marc C Chamberlain
Journal: Neuro-Oncology (2020)

Leptomeningeal metastases (LM) is an uncommon complication of cancer where the overall incidence is <3% regardless of whether originating from a solid or a hematologic primary cancer.Less common still is the development of LM in primary brain tumors where a gradient of cerebrospinal fluid (CSF)-disseminated disease occurrence is seen when comparing differing brain tumor histologies.LM is considered rare in gliomas and by comparison relatively frequent (depending upon the molecular subtype, the incidence may be as high as 30%) in medulloblastoma, pineoblastoma, and atypical teratoid rhabdoid tumor.2][3] All 3 guidelines use a composite score to assess overall response in LM that includes a qualitative assessment of the neurologic exam derived from the Neurologic Assessment in Neuro-Oncology (NANO) proposal. 4In addition, these guidelines incorporate elements of cranial nerve and spinal cord dysfunction relevant to clinical manifestations of LM, a determination of CSF cytology, and MRI assessment of the neuraxis.The proposals differ primarily in how the assessment of the primary brain tumor or systemic cancer is incorporated into the overall response.Peng et al in this journal utilize the RAPNO criteria in a retrospective study from 4 Chinese centers to assess its applicability in 269 pediatric patients ranging in age from 1 month to 18 years with a variety of tumor types. 5Approximately two thirds of patients were diagnosed with either medulloblastoma or high-grade glioma (HGG).The remaining patients were a heterogeneous group that included germ cell, embryonal, and choroid plexus tumors.No molecular subtyping of tumors was reported.Approximately 25% of tumors at presentation were diagnosed with CSF-disseminated disease, although no details were included indicating the primary tumor histology.As stated above, LM would be quite uncommon in patients with HGG whether at diagnosis or at progression.Further, CSF dissemination is comparatively
Clinical and microbiological features of infections during post-operative period after heart transplantation
Authors: Eduardo Barge Caballero, Marisa Crespo Leiro, Alfonso Castro Beiras, María Jesús Paniagua Martín, Zulaika Grille Cancela, Raquel Marzoa Rivas, Javier Muñiz García, Paula Fernández Ugidos, Rocío Gómez López, Pablo Vidal Cortes
Journal: Intensive Care Medicine (2012)